News and Announcements
Actinogen Medical CEO Interview
- Published September 23, 2016 11:18AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.
Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.
Executive Interviews
The $3.5 Trillion Succession Wave: Why 48% of Australian Business Owners Are About to Destroy Value
Australia’s Largest Wealth Transfer Has No Exit Plan Australian business succession planning is broken. An estimated $3.5 trillion in assets will pass from Baby Boomers to younger generations over the next two decades. The numbers reveal a crisis. 48% of Baby Boomer business owners plan to exit within five years. Only 24% have formal succession […]
The Great Life Science Reset: Why the “Sick Care” Model is Failing
The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.
Australia’s A$4 Trillion Generational Pivot
Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]
Backed By Leading Investment Groups and Family Offices
